Oxford, UK – Vaccitech Ltd announces that the European Medicines Agency (EMA) has today recommended the conditional marketing authorisation of the ChAdOx1 nCoV-19 coronavirus vaccine developed by the University of Oxford with its partner AstraZeneca. Distribution will begin across all 27 member states once the decision is ratified by the European Commission. The vaccine was co-invented by Vaccitech and The University of Oxford’s Jenner Institute.
{iframe}https://www.vaccitech.co.uk/european-medicines-agency-recommends-conditional-marketing-authorisation-to-chadox1-coronavirus-vaccine/{/iframe}